1887

Abstract

Foreign viral proteins expressed by rabies virus (RV) have been shown to induce potent humoral and cellular immune responses in immunized animals. In addition, highly attenuated and, therefore, very safe RV-based vectors have been constructed. Here, an RV-based vaccine vehicle was utilized as a novel vaccine against severe acute respiratory syndrome coronavirus (SARS-CoV). For this approach, the SARS-CoV nucleocapsid protein (N) or envelope spike protein (S) genes were cloned between the RV glycoprotein G and polymerase L genes. Recombinant vectors expressing SARS-CoV N or S protein were recovered and their immunogenicity was studied in mice. A single inoculation with the RV-based vaccine expressing SARS-CoV S protein induced a strong SARS-CoV-neutralizing antibody response. The ability of the RV-SARS-CoV S vector to confer immunity after a single inoculation makes this live vaccine a promising candidate for eradication of SARS-CoV in animal reservoirs, thereby reducing the risk of transmitting the infection to humans.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80844-0
2005-05-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/5/vir861435.html?itemId=/content/journal/jgv/10.1099/vir.0.80844-0&mimeType=html&fmt=ahah

References

  1. Aubert, M. F. A., Masson, E., Artois, M. & Barrat, J. ( 1994; ). Oral wildlife rabies vaccination field trails in Europe with recent emphasis on France. In Lyssaviruses, pp. 219–243. Edited by C. E. Rupprecht, B. Dietzschold & H. Koprowski. Berlin, Heidelberg, New York: Springer.
  2. Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, P. L., Murphy, B. R., Subbarao, K. & Moss, B. ( 2004; ). Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 101, 6641–6646. (Epub 2004 Apr 19).[CrossRef]
    [Google Scholar]
  3. Dietzschold, B., Faber, M. & Schnell, M. J. ( 2003; ). New approaches to the prevention and eradication of rabies. Expert Rev Vaccines 2, 399–406.[CrossRef]
    [Google Scholar]
  4. Drosten, C., Gunther, S., Preiser, W. & 23 other authors ( 2003; ). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348, 1967–1976.[CrossRef]
    [Google Scholar]
  5. Foley, H. D., McGettigan, J. P., Siler, C. A., Dietzschold, B. & Schnell, M. J. ( 2000; ). A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc Natl Acad Sci U S A 97, 14680–14685.[CrossRef]
    [Google Scholar]
  6. Foley, H. D., Otero, M., Orenstein, J. M., Pomerantz, R. J. & Schnell, M. J. ( 2002; ). Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J Virol 76, 19–31.[CrossRef]
    [Google Scholar]
  7. Guan, Y., Zheng, B. J., He, Y. Q. & 15 other authors ( 2003; ). Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302, 276–278.[CrossRef]
    [Google Scholar]
  8. Holmes, K. V. ( 2003; ). SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 111, 1605–1609.[CrossRef]
    [Google Scholar]
  9. Lafon, M., Lafage, M., Martinez-Arends, A., Ramirez, R., Vuillier, F., Charron, D., Lotteau, V. & Scott-Algara, D. ( 1992; ). Evidence for a viral superantigen in humans. Nature 358, 507–510.[CrossRef]
    [Google Scholar]
  10. McGettigan, J. P., Foley, H. D., Belyakov, I. M., Berzofsky, J. A., Pomerantz, R. J. & Schnell, M. J. ( 2001a; ). Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol 75, 4430–4434.[CrossRef]
    [Google Scholar]
  11. McGettigan, J. P., Sarma, S., Orenstein, J. M., Pomerantz, R. J. & Schnell, M. J. ( 2001b; ). Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol 75, 8724–8732.[CrossRef]
    [Google Scholar]
  12. McGettigan, J. P., Naper, K., Orenstein, J., Koser, M., McKenna, P. M. & Schnell, M. J. ( 2003a; ). Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol 77, 10889–10899.[CrossRef]
    [Google Scholar]
  13. McGettigan, J. P., Pomerantz, R. J., Siler, C. A., McKenna, P. M., Foley, H. D., Dietzschold, B. & Schnell, M. J. ( 2003b; ). Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 77, 237–244.[CrossRef]
    [Google Scholar]
  14. McKenna, P. M., Pomerantz, R. J., Dietzschold, B., McGettigan, J. P. & Schnell, M. J. ( 2003; ). Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. J Virol 77, 12782–12794.[CrossRef]
    [Google Scholar]
  15. Meslin, F.-X., Fishbein, D. B. & Matter, H. C. ( 1994; ). Rationale and prospects for rabies elimination in developing countries. In Lyssaviruses, pp. 1–26. Edited by B. D. C. E. Rupprecht & H. Koprowski. Berlin, Heidelberg, New York: Springer.
  16. Morimoto, K., Foley, H. D., McGettigan, J. P., Schnell, M. J. & Dietzschold, B. ( 2000; ). Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J Neurovirol 6, 373–381.[CrossRef]
    [Google Scholar]
  17. Morimoto, K., McGettigan, J. P., Foley, H. D., Hooper, D. C., Dietzschold, B. & Schnell, M. J. ( 2001a; ). Genetic engineering of live rabies vaccines. Vaccine 19, 3543–3551.[CrossRef]
    [Google Scholar]
  18. Morimoto, K., Schnell, M. J., Pulmanausahakul, R., McGettigan, J. P., Foley, H. D., Faber, M., Hooper, D. C. & Dietzschold, B. ( 2001b; ). High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. J Immunol Methods 252, 199–206.[CrossRef]
    [Google Scholar]
  19. Orciari, L. A., Niezgoda, M., Hanlon, C. A., Shaddock, J. H., Sanderlin, D. W., Yager, P. A. & Rupprecht, C. E. ( 2001; ). Rapid clearance of SAG-2 rabies virus from dogs after oral vaccination. Vaccine 19, 4511–4518.[CrossRef]
    [Google Scholar]
  20. Peiris, J. S., Lai, S. T., Poon, L. L. & 14 other authors ( 2003; ). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361, 1319–1325.[CrossRef]
    [Google Scholar]
  21. Reed, L. J. & Muench, H. ( 1938; ). A simple method of estimating fifty percent endpoints. Am J Hyg 27, 493–497.
    [Google Scholar]
  22. Rota, P. A., Oberste, M. S., Monroe, S. S. & 32 other authors ( 2003; ). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394–1399.[CrossRef]
    [Google Scholar]
  23. Rupprecht, C. E., Hanlon, C. A., Niezgoda, M., Murphy, S., Schnell, M. J. & Dietzschold, B. ( 2001; ). Oral rabies vaccination of the mongoose, Herpestes auropunctatus. In Rabies in the Americas. XII International Meeting on Advances in Rabies Research and Control in the Americas. Peterborough, Ontario, Canada.
  24. Rupprecht, C. E., Hanlon, C. A., Blanton, J. & 7 other authors ( 2005; ). Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res (in press).
    [Google Scholar]
  25. Schnell, M. J., Mebatsion, T. & Conzelmann, K. K. ( 1994; ). Infectious rabies viruses from cloned cDNA. EMBO J 13, 4195–4203.
    [Google Scholar]
  26. Schnell, M. J., Foley, H. D., Siler, C. A., McGettigan, J. P., Dietzschold, B. & Pomerantz, R. J. ( 2000; ). Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci U S A 97, 3544–3549.[CrossRef]
    [Google Scholar]
  27. Shoji, Y., Inoue, S., Nakamichi, K., Kurane, I., Sakai, T. & Morimoto, K. ( 2004; ). Generation and characterization of P gene-deficient rabies virus. Virology 318, 295–305.[CrossRef]
    [Google Scholar]
  28. Siler, C. A., McGettigan, J. P., Dietzschold, B., Herrine, S. K., Dubuisson, J., Pomerantz, R. J. & Schnell, M. J. ( 2002; ). Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292, 24–34.[CrossRef]
    [Google Scholar]
  29. Subbarao, K., McAuliffe, J., Vogel, L. & 7 other authors ( 2004; ). Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78, 3572–3577.[CrossRef]
    [Google Scholar]
  30. Wiktor, T. J., Macfarlan, R. I., Foggin, C. M. & Koprowski, H. ( 1984; ). Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand 57, 199–211.
    [Google Scholar]
  31. Yang, Z. Y., Kong, W. P., Huang, Y., Roberts, A., Murphy, B. R., Subbarao, K. & Nabel, G. J. ( 2004; ). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561–564.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80844-0
Loading
/content/journal/jgv/10.1099/vir.0.80844-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error